Literature DB >> 25180149

Frequencies of CD4+ T Regulatory Cells and their CD25(high) and FoxP3(high) Subsets Augment in Peripheral Blood of Patients with Acute and Chronic Brucellosis.

Abbas Bahador1, Jamshid Hadjati2, Niloofar Hassannejad3, Hadi Ghazanfari2, Mohammadreza Maracy4, Sirous Jafari5, Maryam Nourizadeh6, Amirhooshang Nejadeh7.   

Abstract

OBJECTIVES: Brucellosis remains one of the most common zoonotic diseases worldwide. In humans, brucellosis can be a serious, debilitating, and sometimes chronic disease. Different mechanisms can be postulated as to the basis for the induction of the chronic status of infectious diseases that T regulatory cells are one of the most important related mechanisms. The current study was designed to determine whether percentage of CD4+Treg cells and their CD25(high) and FoxP3(high) subpopulations in peripheral blood are changed in human brucellosis samples in comparison to a control group.
METHODS: In total, 68 brucellosis patients (acute form: n = 43, chronic form: n = 25) and 36 healthy volunteers entered our study. After isolating of peripheral blood mononuclear cells, heparinized venous blood samples were obtained from both patients and healthy donors, CD4, CD25, and FoxP3 molecules were evaluated by two- and three-color flow cytometric methods.
RESULTS: The results revealed a new finding in relation to Treg cells and human brucellosis. The numbers of CD4(+)Treg cells and their CD25(high) and FoxP3(high) subsets increase significantly in the peripheral blood of acute and chronic forms of brucellosis samples compared with healthy groups, with this increase being greater in the chronic group.
CONCLUSION: There seems to be a correlation between increase of CD4+Treg cells and their subsets and the disease progress from healthy state to acute and chronic brucellosis.

Entities:  

Keywords:  CD25high subsets; CD4+ T regulatory cells; FoxP3high subsets; brucellosis

Year:  2014        PMID: 25180149      PMCID: PMC4147229          DOI: 10.1016/j.phrp.2014.04.008

Source DB:  PubMed          Journal:  Osong Public Health Res Perspect        ISSN: 2210-9099


Introduction

Brucellosis is an intracellular bacterial infection with worldwide distribution with > 500,000 human cases reported annually [1,2]. The disease is caused by organisms of the genus Brucella, especially by Brucella melitensis, and is known as the most common zoonotic disease [3]. In humans, the disease culminates in high clinical morbidity and diverse clinical manifestations, as any organ can be affected [4]. Despite early diagnosis and treatment, approximately 10–30% of patients develop chronic disease [5,6]. Host protection against intracellular pathogens such as Brucella spp. depends on cell-mediated immunity (CMI) [7,8]. Brucella can survive within macrophages of the host and invades the normal mechanisms of bacterial killing, causing chronic disease [6,7]. Th1 related cytokines [interleukin (IL)-12 and interferon-γ], which are fundamental for the clearance of brucellosis agent, and percentages of ex vivo and phytohemagglutinin (PHA)-cultured CD4+ T lymphocytes are found to be diminished in chronic patients [9-11]. In recent years, regulatory T cells (Tregs) have become a popular subject for immunological research. Numerous reports shed light on the major aspects of Treg biology in humans, with the characterization of different T-cell subpopulations, including naturally occurring CD4+ CD25+Tregs, induced Tregs [IL-10 producing CD4+ type I regulatory T cells (Tr1) and T helper type 3 (Th3) cells], and CD4+ CD25+ T cells that develop in the periphery by conversion of CD4+ CD25– T cells. All these different T-cell populations with regulatory function coexist and contribute to immune suppression [12-14]. There is now considerable evidence that CD4+ CD25+ Tregs represent a stable population of peripheral lymphocytes. These CD4+ CD25+ Tregs represent about 5–10% of human CD4+ T cells, and are commonly identified by the constitutive expression of IL-2 receptor α (IL-2Ra; CD25), as well as the transcription factor scurfin, encoded by the forkhead family transcription factor 3 (Foxp3) gene [15], and are also characterized by their very low levels of proliferation on T-cell receptor (TCR) stimulation in vitro. The CD4+ CD25high subset (which has high levels of CD25 expression) in normal individuals comprises about 1–3% of human circulating CD4+ T cells. Unlike the total population of CD4+ CD25+ T cells, these CD4+ CD25high cells constitutively expressing FoxP3 molecules at high levels can significantly inhibit the proliferation and cytokine secretion induced by TCR cross-linking of CD4+ CD25− responder T cells, CD8+ T cells, dendritic cells, natural killer cells, and B cells [16-20]. However, FoxP3 is emerged transiently in CD25low CD4+T lymphocytes, which may be without suppressive activities; but they contain effector functions [21]. The role of CD4+CD25hiT and CD4+FoxP3hiT cells in immunopathology of Brucella infection has not yet been elucidated [22]. So, in our study these cells were evaluated to determine two substantial questions: is the frequency of CD4+CD25highT, CD4+FoxP3highT, CD4+CD25highFoxP3+, and CD4+CD25+FoxP3high cells increased in the peripheral blood (PB) of patients with acute or chronic brucellosis as a direct result and, if so, can these Treg cells impinge on antibacterial immune responses as an inductive result, like other infectious diseases.

Materials and methods

Participants

There were 104 unrelated participants enrolled in the study: 68 brucellosis patients; and 36 healthy age- and gender-matched volunteers who were used as controls. According to disease history, clinical picture, and laboratory findings, patients were divided into acute (AB) and chronic (CB) brucellosis groups (Table 1).
Table 1

Demographic data of the groups (acute, chronic, and control) studied

ABCBHealthy control
N432536
Female14813
Male291723
Age (mean ± standard deviation, y)43.5 ± 19.248.7 ± 14.342.6 ± 15.2

AB = acute brucellosis; CB = chronic brucellosis.

The AB group included 43 consecutive patients. All AB patients had a disease duration ≤8 weeks (mean ± standard deviation, 3.5 ± 2.3 weeks). The diagnosis was based on compatible clinical picture (Table 2) in combination to high serum titers of anti-brucellar antibodies or fourfold increase of the initial titers in two paired samples drawn 2 weeks apart. In addition, in 19 out of 43 AB patients, Brucella melitensis was isolated in blood culture. In 33 patients brucellar DNA was detected by PCR analysis in the blood and the serum.
Table 2

Clinical characteristic of the patient groups studied

AB (n = 43)CB (n = 25)
Symptoms
Fever436
Sweating273
Chills305
Malaise/fatigue2417
Arthalgias1910
Lumbar pain166
Headache13
Myalgias1110
Focal disease
Spondylitis53
Sacroiliitis3
Epididymoorchitis3
Meningoencephalitis6

AB = acute brucellosis; CB = chronic brucellosis.

The CB group was composed of 25 patients. All CB patients had disease duration ≥6 months [23]. Thirteen of 22 CB patients had also positive PCR analysis in the blood. High specific titers were defined by anti-brucellar antibodies, which were considered for the Wright agglutination test ≥1:320, for the Coombs' agglutination test ≥1:320, and for the complement fixation test ≥32. Healthy volunteers were tested serologically for brucellosis and found to be negative.

Flow cytometry

Surface CD4 and CD25, and intracellular FoxP3 expression were assessed by flow cytometry using the eBioscience human regulatory T cell staining kit Number 3 (eBioscience, San Diego, CA, USA). In brief, PB mononuclear cells (PBMCs) were obtained by Ficoll–Hypaque density gradient centrifugation. Cells were incubated with FITC anti-human CD4 (RPA-T4) and PE anti-human CD25 (BC96) for 30 minutes at 4°C.Then, after twice washing and fixing with fixation/permeabilization solutions, the cells were stained with PE-Cy5 anti-human FoxP3 (PH101), and incubated similarly. Finally, two- and three-color fluorescence flow cytometric analysis by a BD FACS Calibur system were used to demonstrate the frequency of CD4+CD25+, CD4+ FoxP3+ and CD4+CD25+FoxP3+ cells in PB samples.

Statistical analysis

Parametric statistical tests were applied as the variables were distributed normally (Kolmogorov–Smirnov test). Data were analyzed by one-way analysis of variance using SPSS version 21 (SPSS Inc., Chicago, IL, USA) and were represented as mean ± SD. A p value <0·05 was considered to be statistically significant.

Ethics statement

Our study was confirmed by the ethical committee of Tehran University of Medical Sciences, Tehran, Iran. The participants were informed about the study and they chose whether or not to participate in this study.

Results

CD4+Treg cells and their subsets

The percentages of Treg cells were calculated as the frequencies of CD4+CD25+, CD4+CD25high, CD4+FoxP3+, CD4+FoxP3high, CD4+CD25+FoxP3+, CD4+CD25highFoxP3+, and CD4+CD25+FoxP3high cells in the CD4+ population of PBMCs, and their frequencies were 6.7%, 2.0%, 1.5%, 0.4%, 1.4%, 0.41%, and 0.4% of CD4+ cells, respectively, in PBMCs of healthy age-matched controls (Table 3, Figures 1 and 2). FoxP3+ cells, similar to CD25+cells, were classified into two subsets (FoxP3high and FoxP3low) based on the intensity of FoxP3 expression (Figure 3).
Table 3

Frequencies of Treg cell subsets determined by surface markers (CD4 and CD25) and intracellular FoxP3 levels (p < 0.01)

ControlAcuteChronic
Expression of surface markers (%)
CD4+CD25+ cells6.7 ± 1.816.6 ± 4.227.6 ± 6.4
CD4+CD25low cells4.7 ± 1.312.6 ± 3.421.2 ± 4.6
CD4+CD25high cells2.0 ± 0.53.9 ± 1.16.8 ± 2.1
Expression of intracellular Foxp3 molecule (%)
CD4+Foxp3+cells1.5 ± 0.65.7 ± 1.810.6 ± 2.5
CD4+Foxp3low cells1.2 ± 0.54.0 ± 1.27.7 ± 1.5
CD4+Foxp3high cells0.4 ± 0.21.6 ± 0.42.9 ± 0.60
CD4+CD25+FoxP3+cells1.4 ± 0.485.06 ± 1.379.5 ± 2.06
CD4+CD25lowFoxP3+cells1.11 ± 0.53.76 ± 0.947.09 ± 1.25
CD4+CD25highFoxP3+cells0.41 ± 0.181.28 ± 0.472.45 ± 0.57
CD4+CD25+FoxP3lowcells1.18 ± 0.483.57 ± 1.115.28 ± 1.32
CD4+CD25+FoxP3highcells0.4 ± 0.21.41 ± 0.382.03 ± 0.4

Data are presented as mean ± SD.

Figure 3

Classification of CD4+FoxP3+ cells based on levels of intracellular FoxP3 expression (FoxP3high and FoxP3low) via flow cytometric two-color method.

The proportions of CD4+CD25+ cells included 16.6% in AB and 27.6% in CB patients. Also, the CD25high subset of these cells contained 3.9% in AB and 6.8% in CB patients (Table 3, Figures 1 and 2). CD4+FoxP3+ cells accounted for 5.7% of CD4+T-cells in AB and 10.6% of CD4+T cells in CB patients. In total CD4+lymphocytes, FoxP3high subpopulation consisted of 1.6% and 2.9% in AB and CB, respectively. In patients with AB, CD4+CD25+FoxP3+cells comprised 5.06% of total CD4+ lymphocytes; in CB patients, percentage of these cells was 9.5% of total CD4+ lymphocytes (Table 3). CD4+CD25highFoxP3+cells subtended 1.28% of CD4+ lymphocytes in AB and 2.45% in CB patients. Moreover, frequencies of CD4+CD25+FoxP3high cells encompassed 1.41% and 2.03% of CD4+ lymphocytes in attribution of AB and CB patients, respectively (Table 3, Figure 3).

Correlation between the level of CD25 expression in CD4+ lymphocytes and CD4+FoxP3+cells

Correlation coefficients of CD4+CD25high cells and CD4+FoxP3+ cells in the three groups consisted of R = 0.792, p < 0.001 (healthy control), R = 0.817, p < 0.001 (AB), and R = 0.661, p < 0.001 (CB) versus correlation between CD4+CD25low cells and CD4+FoxP3+ cells with coefficients including R = 0.680, p < 0.001 (healthy control), R = 0.586, p < 0.001 (AB), and R = 0.483, p = 0.014 (CB; Figure 4).
Figure 4

Correlation of CD4+FoxP3+ cells with CD4+CD25+ cells. CD4+CD25high cells exhibited more vigorous power of coefficient to CD4+FoxP3+ cells than to CD4+CD25low T cells in all three groups (control, acute brucellosis, chronic brucellosis). Each row was assigned to the one group, in which the left and the right diagrams depict the correlation among frequencies of CD4+FoxP3+ cells with CD4+CD25low or CD4+CD25high cells, respectively.

Discussion

Regulatory T cells (Treg cells) were originally identified through their function in controlling autoimmunity, where they mediate immunological tolerance to self-antigens [24]. However, it later became apparent that Treg cells also control immune responses to foreign antigens on pathogens [25]. The function of Treg cells during infection appears to be primarily to prevent collateral damage from unrestrained immune responses to the pathogen, with a number of studies demonstrating enhanced immunopathology with defective or depleted Treg cells. It also seems that the induction of Treg cells during infection is an immune subversion strategy engaged by certain pathogens in order to last their survival in the host [26]. In agreement with other studies [11,27], we found that the percentage expression of IL-2 receptor α on peripheral CD4+lymphocytes in the healthy group was <10% (data not shown). Also, in the current study, > 90% of FoxP3+ cells in all three groups were CD4+FoxP3+ (data not shown), which implies that the majority of FoxP3+Treg cells in healthy individuals, AB, and CB patients manifest surface CD4 molecules. In our study, the percentage of peripheral CD4+CD25+(low or high) T-lymphocytes was increased in AB patients, as compared to controls, suggesting that helper T-cells are activated in AB. This finding adds further support to data presented by other researchers [11,28,29] and it approves that CD25 is upregulated in AB patients. CB patients showed significantly increased percentage of CD25 expression on peripheral CD4+CD25high lymphocytes in comparison to AB patients. This seems to be in contrast with a previous study by Skendros et al [11], which showed diminished percentage in CD25 expression on peripheral CD4+T cells in compared with AB. But, they use PHA in the culture of obtained PBMC for activating and proliferating of lymphocytes and for this the acute brucellosis group has the higher level of CD4+CD25low cells as CD4+T-helper cells, were activated and proliferated more than other groups. By contrast, the increase of CD4+CD25high cells in PB of CB patients and induced suppression of T cells by this Treg cells, appears to be a substantial reason for the significant reduction in the percentage of PHA-proliferating TCD4+CD25+ cells and anergy induction in CB [30]. In addition, in our research, there were significant increases in the proportions of CD4+FoxP3+cells and their FoxP3high subpopulation, as well as CD4+CD25+FoxP3+ cells and their CD25high or FoxP3high subsets in CB in comparison to AB patients and healthy controls. Also, CD4+CD25high Treg cells in the AB group showed a significant increase in frequencies compared with the control group. According to Curiel et al [31], FoxP3 expression in low levels can cause differentiation of Treg cells to Th2 or Th17 cells. So, the intensity of FoxP3 expression is crucial in the state of Treg suppressive activity. In fact, the presence of FoxP3 molecule maybe not only function as an on-and-off switch to offer suppressive activity of Treg cells but also control the regulatory capacity of these cells owing to the decreased function of Treg cells due to attenuated FoxP3 expression [32]. Consequently, our report about an increase of FoxP3+CD4+Treg subsets in AB and CB patients versus control volunteers indicates a significant rising trend in suppressive activities of the immune response in parallel with an ongoing infection such as brucellosis. By contrast, we found the relationship between CD4+CD25high and CD4+FoxP3+ cells displayed a stronger power of correlation coefficient than CD4+CD25low and CD4+FoxP3+ cells in all three groups. This positive correlation verifies the direct relationship between the high-level intensity of CD25 (CD25high) and FoxP3 expression. Also, the AB group (R = 0.817) showed a better correlation of CD4+CD25high and CD4+FoxP3+ cells compared with the two other groups [R(healthy group) = 0.792; R(CB) = 0.661], which may be due to the larger sample size of the AB group (Figure 4). In conclusion, our results demonstrate that there is a marked increase in circulating CD4+ CD25+, CD4+FoxP3+, and CD4+CD25+FoxP3+ Tregs and their CD25high or FoxP3high subpopulations in AB and CB patients. Tregs play a negative role not only in modulating the effectors of immune responses by inhibiting interferon-γ secretion and cellular proliferation upon Brucella antigen stimulation, but also in influencing the disease persistence in CB. These findings suggest that modulation of CD4+ CD25+ Tregs might be one potential therapeutic strategy for the treatment of the chronic form of this infection. However, this study was limited by analysis of the PB compartment only, and further detailed investigation of the level and function of CD4+ CD25+ and CD4+FoxP3+Tregs in brucellosis needs to be carried out.

Conflicts of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.
  32 in total

Review 1.  Antigen-induced regulatory T cells.

Authors:  Stephane Vigouroux; Eric Yvon; Ettore Biagi; Malcolm K Brenner
Journal:  Blood       Date:  2004-03-16       Impact factor: 22.113

2.  Cutting edge: direct suppression of B cells by CD4+ CD25+ regulatory T cells.

Authors:  Hyung W Lim; Peter Hillsamer; Allison H Banham; Chang H Kim
Journal:  J Immunol       Date:  2005-10-01       Impact factor: 5.422

Review 3.  Brucellosis.

Authors:  Georgios Pappas; Nikolaos Akritidis; Mile Bosilkovski; Epameinondas Tsianos
Journal:  N Engl J Med       Date:  2005-06-02       Impact factor: 91.245

4.  Diminished percentage of CD4+ T-lymphocytes expressing interleukine-2 receptor alpha in chronic brucellosis.

Authors:  Panagiotis Skendros; Panagiota Boura; Dimitrios Chrisagis; Maria Raptopoulou-Gigi
Journal:  J Infect       Date:  2006-05-23       Impact factor: 6.072

Review 5.  Brucellosis: a re-emerging zoonosis.

Authors:  Mohamed N Seleem; Stephen M Boyle; Nammalwar Sriranganathan
Journal:  Vet Microbiol       Date:  2009-06-21       Impact factor: 3.293

6.  Plasmodium vivax: induction of CD4+CD25+FoxP3+ regulatory T cells during infection are directly associated with level of circulating parasites.

Authors:  Lilian Lacerda Bueno; Cristiane Guimarães Morais; Fernanda Fortes Araújo; Juliana Assis Silva Gomes; Rodrigo Corrêa-Oliveira; Irene Silva Soares; Marcus Vinícius Lacerda; Ricardo Toshio Fujiwara; Erika Martins Braga
Journal:  PLoS One       Date:  2010-03-10       Impact factor: 3.240

7.  Diminished production of T helper 1 cytokines correlates with T cell unresponsiveness to Brucella cytoplasmic proteins in chronic human brucellosis.

Authors:  Guillermo H Giambartolomei; M Victoria Delpino; Mariela E Cahanovich; Jorge C Wallach; Pablo C Baldi; Carlos A Velikovsky; Carlos A Fossati
Journal:  J Infect Dis       Date:  2002-06-17       Impact factor: 5.226

8.  Dominant Th1 cytokine production in early onset of human brucellosis followed by switching towards Th2 along prolongation of disease.

Authors:  Alireza Rafiei; Sussan K Ardestani; Amina Kariminia; Abdolhosein Keyhani; Mino Mohraz; Aref Amirkhani
Journal:  J Infect       Date:  2006-02-20       Impact factor: 6.072

9.  CD4+CD25+ T regulatory cells inhibit cytotoxic activity of T CD8+ and NK lymphocytes in the direct cell-to-cell interaction.

Authors:  Piotr Trzonkowski; Ewa Szmit; Jolanta Myśliwska; Anita Dobyszuk; Andrzej Myśliwski
Journal:  Clin Immunol       Date:  2004-09       Impact factor: 3.969

Review 10.  Role of regulatory T cells and FOXP3 in human diseases.

Authors:  Rosa Bacchetta; Eleonora Gambineri; Maria-Grazia Roncarolo
Journal:  J Allergy Clin Immunol       Date:  2007-08       Impact factor: 10.793

View more
  5 in total

1.  Evaluation of Regulatory T Cells in Patients with Acute and Chronic Brucellosis.

Authors:  Ali Ganji; Ghasem Mosayebi; Ehsanollah Ghaznavi-Rad; Khadije Khosravi; Nader Zarinfar
Journal:  Rep Biochem Mol Biol       Date:  2017-04

Review 2.  Meta-Analysis of the Changes of Peripheral Blood T Cell Subsets in Patients with Brucellosis.

Authors:  Rongjiong Zheng; Songsong Xie; Shaniya Niyazi; Xiaobo Lu; Lihua Sun; Yan Zhou; Yuexin Zhang; Kai Wang
Journal:  J Immunol Res       Date:  2018-05-17       Impact factor: 4.818

3.  Immune effects of CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer: Relief from immunosuppression is associated with clinical response.

Authors:  Fabio Scirocchi; Simone Scagnoli; Andrea Botticelli; Alessandra Di Filippo; Chiara Napoletano; Ilaria Grazia Zizzari; Lidia Strigari; Silverio Tomao; Enrico Cortesi; Aurelia Rughetti; Paolo Marchetti; Marianna Nuti
Journal:  EBioMedicine       Date:  2022-04-25       Impact factor: 11.205

Review 4.  Immunosuppressive Mechanisms in Brucellosis in Light of Chronic Bacterial Diseases.

Authors:  Joaquin Miguel Pellegrini; Jean-Pierre Gorvel; Sylvie Mémet
Journal:  Microorganisms       Date:  2022-06-21

5.  Exploring cannabidiol effects on inflammatory markers in individuals with cocaine use disorder: a randomized controlled trial.

Authors:  Jean-François Cailhier; Didier Jutras-Aswad; Florence Morissette; Violaine Mongeau-Pérusse; Elie Rizkallah; Paméla Thébault; Stéphanie Lepage; Suzanne Brissette; Julie Bruneau; Simon Dubreucq; Emmanuel Stip
Journal:  Neuropsychopharmacology       Date:  2021-07-30       Impact factor: 7.853

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.